Parkinson's Disease

With the advent of major organizations like the Michael J. Fox Foundation, Parkinson's research has never been busier. Current trials have focused on new symptomatic therapies and new methods of early diagnosis.

Condition(s) Type of Drug Phase Add-On Comparator Duration Open Label Extension
New Onset Parkinson's Disease Novel Oral Dopamine Agonist III No Placebo 24 weeks 9 months
Dyskinesias in Parkinson's Disease Novel oral agent II Yes 50% 12 weeks No

Response Form

If you or a loved one is interested in participating in one of our trials, please contact us at (855) 829-8899 or use the form below. One of our skilled Clinical Research Coordinators will contact you as soon as possible. Thank you for your interest in our research!

- Stephen S. Flitman, MD, Medical Director

Your Name
Name of Patient
Email Address
Your Telephone
Best Time to Call